gip/glp-1 tirzepatide Microdosed The Science Behind Tirzepatide: GLP-1
Description
The half-life of a drug is the amount of time it takes for half of it to be cleared from your bloodstream
The GIP component amplifies insulin release and may reduce GLP-1-related nausea a key tolerability advantage over pure GLP-1 agonists like semaglutide
Various mechanisms have been theorized to describe how dual agonism, as GLP-1 RA, could directly reduce triglycerides hepatocyte storage, lipogenesis and improving hepatic glucose metabolism (96) and promoting lipolysis and fatty acid oxidation (97)
On April 17, 2024, Eli Lilly announced that the phase III SURMOUNT-OSA clinical study of tirzepatide for the treatment of moderate to severe obstructive sleep apnea (OSA) combined with obesity reached the main endpoint
Protein intake should increase to at least 1 gram per pound of lean body mass
For more robust reminders, you can use your iPhone's built-in Reminders app or a dedicated medication reminder app alongside OffGrid Dose
